NEW YORK & CALGARY, Alberta– Orpyx Medical Technologies Inc. (Orpyx®), the leader in diabetic foot ulcer (DFU) and amputation prevention, announced the completion of an additional $20 million in growth capital led by Perceptive Advisors.
“Orpyx is an innovator in diabetic foot ulcer prevention,” said Sam Chawla, Portfolio Manager at Perceptive Advisors. “We are excited to partner with the company to support the mission of improving the lives of people at risk from the impacts of peripheral neuropathy and diabetes.”
The Orpyx® Sensory Insole system enhances standard custom orthotics by integrating advanced multi-modal sensor technology that allows for continuous remote monitoring, backed by a dedicated team of specialized nurses. This system monitors critical parameters such as plantar pressure, temperature, activity, and adherence, which are essential for preventing debilitating foot complications in individuals with diabetes and neuropathy.
“We’re proud to partner with Perceptive Advisors, whose belief in our mission will help us make an even greater impact on the lives of people managing diabetes,” said Dr. Breanne Everett, CEO of Orpyx. “Together, we’re not just advancing technology—we’re saving limbs, extending mobility, and enhancing the healthspan of those facing the serious complications of diabetic foot disease. This partnership allows us to accelerate our commercial efforts in delivering life-changing solutions to patients and healthcare providers, ultimately improving outcomes for those most in need.”
